These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33796257)

  • 1. Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database.
    Almutairi AR; Slack M; Erstad BL; McBride A; Abraham I
    Ther Adv Drug Saf; 2021; 12():2042098621991279. PubMed ID: 33796257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data.
    Almutairi AR; Erstad BL; McBride A; Slack M; Abraham I
    Expert Opin Drug Saf; 2021 Apr; 20(4):489-497. PubMed ID: 33445985
    [No Abstract]   [Full Text] [Related]  

  • 3. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
    Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
    ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit.
    Patel AB; Farooq S; Welborn M; Amaria RN; Chon SY; Diab A; Glitza Oliva IC; Huen AO; Li SQ; Nelson KC; Pacha O; Patel SP; Rapini RP; Tawbi HA; Wong MK; McQuade J; Davies MA; Haydu LE
    Cancer; 2022 Mar; 128(5):975-983. PubMed ID: 34724197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes.
    Lui DTW; Lee CH; Tang V; Fong CHY; Lee ACH; Chiu JWY; Leung RCY; Kwok GGW; Li BCW; Cheung TT; Woo YC; Lam KSL; Yau T
    Endocr Pract; 2021 Sep; 27(9):886-893. PubMed ID: 33581327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
    Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
    Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.
    Teo AYT; Yau CE; Low CE; Pereira JV; Ng JYX; Soong TK; Lo JYT; Yang VS
    EClinicalMedicine; 2024 Nov; 77():102870. PubMed ID: 39416390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor.
    Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
    Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
    JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
    Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
    Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.
    Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H
    Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.
    Brown LJ; Weppler A; Bhave P; Allayous C; Patrinely JR; Ott P; Sandhu S; Haydon A; Lebbe C; Johnson DB; Long GV; Menzies AA; Carlino MS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
    Lupu J; Herrscher H; Robert C
    Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials.
    Zhao BW; Zhang FY; Wang Y; Chen GM; Nie M; Zhao ZK; Chen XJ; Jiang KM; Nie RC; Chen YB
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291763
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma.
    Fujimura T; Muto Y; Asano Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
    Almutairi AR; McBride A; Slack M; Erstad BL; Abraham I
    Front Oncol; 2020; 10():91. PubMed ID: 32117745
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.